Review
doi: 10.2174/1567205053585954.
C-1073 (mifepristone) in the adjunctive treatment of Alzheimer's disease
Affiliations
- PMID: 15974908
- DOI: 10.2174/1567205053585954
Item in Clipboard
Review
C-1073 (mifepristone) in the adjunctive treatment of Alzheimer's disease
Curr Alzheimer Res.
2005 Apr.
Abstract
Alzheimer's disease is frequently associated with abnormalities in the hypothalamic pituitary adrenal axis. Elevated cortisol levels in Alzheimer's disease may in turn be associated with a more rapid progression of the illness. In addition, elevated cortisol levels may directly contribute to cognitive deficits in Alzheimer's disease. Mifepristone is a potent antagonist of the glucocorticoid receptor and blocks the central actions of cortisol. The purpose of this study is to determine the effects of glucocorticoid receptor blockade with mifepristone on cognition in Alzheimer's disease.
Similar articles
-
Slowing the progression of cognitive decline in Alzheimer's disease using mifepristone.J Mol Neurosci. 2002 Aug-Oct;19(1-2):201-6. doi: 10.1007/s12031-002-0033-3. J Mol Neurosci. 2002. PMID: 12212781 Clinical Trial.
-
The use of mifepristone in the treatment of neuropsychiatric disorders.Trends Endocrinol Metab. 2006 Apr;17(3):117-21. doi: 10.1016/j.tem.2006.02.006. Epub 2006 Mar 10. Trends Endocrinol Metab. 2006. PMID: 16530421 Review.
-
New selective glucocorticoid receptor modulators reverse amyloid-β peptide-induced hippocampus toxicity.Neurobiol Aging. 2016 Sep;45:109-122. doi: 10.1016/j.neurobiolaging.2016.05.018. Epub 2016 May 27. Neurobiol Aging. 2016. PMID: 27459932
-
The effect of mifepristone (RU 486) on plasma cortisol in Alzheimer's disease.Neurochem Res. 2006 May;31(5):585-8. doi: 10.1007/s11064-006-9055-5. Epub 2006 May 23. Neurochem Res. 2006. PMID: 16770728 Clinical Trial.
-
A new therapeutic approach in the medical treatment of Cushing's syndrome: glucocorticoid receptor blockade with mifepristone.Endocr Pract. 2013 Mar-Apr;19(2):313-26. doi: 10.4158/EP12149.RA. Endocr Pract. 2013. PMID: 23337135 Review.
Cited by
-
Effects of stress and stress hormones on amyloid-beta protein and plaque deposition.J Alzheimers Dis. 2009;18(2):459-69. doi: 10.3233/JAD-2009-1152. J Alzheimers Dis. 2009. PMID: 19584430 Free PMC article. Review.
-
Progress in the development of new drugs in Alzheimer's disease.J Nutr Health Aging. 2011 Jan;15(1):45-57. doi: 10.1007/s12603-011-0012-x. J Nutr Health Aging. 2011. PMID: 21267520
-
Risk Factors for Alzheimer's Disease: Focus on Stress.Front Pharmacol. 2019 Sep 10;10:976. doi: 10.3389/fphar.2019.00976. eCollection 2019. Front Pharmacol. 2019. PMID: 31551781 Free PMC article. Review.
-
Preclinical assessment for selectively disrupting a traumatic memory via postretrieval inhibition of glucocorticoid receptors.Biol Psychiatry. 2009 Feb 1;65(3):249-57. doi: 10.1016/j.biopsych.2008.07.005. Epub 2008 Aug 16. Biol Psychiatry. 2009. PMID: 18708183 Free PMC article.
-
Stress increases vulnerability to inflammation in the rat prefrontal cortex.J Neurosci. 2006 May 24;26(21):5709-19. doi: 10.1523/JNEUROSCI.0802-06.2006. J Neurosci. 2006. PMID: 16723527 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
